An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

Carcinoid Tumor Clinical Trial

Official title:

Evaluation of Dual Energy CT for the Detection of Gastrointestinal Carcinoids

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04993261
• Other study ID #: 2014-0578
• Secondary ID: NCI-2019-0247720
• Status: Recruiting
• Phase: Early Phase 1
• Start date: September 23, 2015
• Est. completion date: December 31, 2026

Study information

• Verified date: February 2024
• Source: M.D. Anderson Cancer Center
• Contact: Ajaykumar Morani, MD
• Email: AMorani[@]mdanderson.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial studies the use of a special type of computed (CT) scan called dual energy CT in detecting gastrointestinal carcinoid tumors. CT is an imaging technique that uses x-rays and a computer to create images of areas inside the body. Dual energy computed tomography is a technique used during routine CT scans to help obtain and process the image after the scan is complete. Doctors want to learn if dual energy computed tomography can help improve the detection of carcinoid tumors during routine CT scans.

Description:

PRIMARY OBJECTIVES:

I. Evaluate prospectively the sensitivity and specificity of dual energy computed tomography (CT) in detecting primary gastrointestinal (GI) carcinoid.

OUTLINE:

Patients undergo one dual energy CT scan during scheduled CT scan.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 66
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with: clinical features of carcinoid syndrome (or) increased serum and urinary markers suggestive of carcinoid (or) endoscopic biopsy proven carcinoid (or) metastases which are biopsy proven as carcinoid.

• Patient is scheduled to have a clinically indicated staging CT exam.

• Patients who have signed their informed consent form to undergo the study.

Exclusion Criteria:

• Patients who have already had their primary GI carcinoid resected.

• Contraindication to intravenous contrast agents (e.g. allergy, renal failure, dialysis, pregnancy etc.).

• Pregnant patients.

Related Conditions & MeSH terms

• Carcinoid Syndrome
• Carcinoid Tumor
• Malignant Carcinoid Syndrome
• Metastatic Carcinoid Tumor
• Neoplasms
• Neuroendocrine Tumors
• Serotonin Syndrome

Intervention

Procedure:
• Dual-Energy Computed Tomography
Undergo dual energy CT scan

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity and specificity of dual energy computed tomography in detecting primary gastrointestinal carcinoid tumors		through study completion, an average of 1 year